Dean Investment Associates LLC lessened its position in shares of Pfizer Inc. (NYSE:PFE) by 2.4% in the second quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund owned 176,469 shares of the biopharmaceutical company’s stock after selling 4,266 shares during the period. Pfizer accounts for 0.9% of Dean Investment Associates LLC’s holdings, making the stock its 22nd biggest holding. Dean Investment Associates LLC’s holdings in Pfizer were worth $6,402,000 at the end of the most recent reporting period.
A number of other hedge funds and other institutional investors have also recently made changes to their positions in the stock. BlackRock Inc. grew its holdings in Pfizer by 1.5% in the first quarter. BlackRock Inc. now owns 459,530,944 shares of the biopharmaceutical company’s stock worth $16,308,754,000 after purchasing an additional 6,785,335 shares during the period. Massachusetts Financial Services Co. MA grew its holdings in Pfizer by 0.3% in the second quarter. Massachusetts Financial Services Co. MA now owns 61,881,280 shares of the biopharmaceutical company’s stock worth $2,245,053,000 after purchasing an additional 160,730 shares during the period. Dimensional Fund Advisors LP grew its holdings in Pfizer by 11.9% in the first quarter. Dimensional Fund Advisors LP now owns 47,174,487 shares of the biopharmaceutical company’s stock worth $1,674,223,000 after purchasing an additional 4,998,981 shares during the period. Fisher Asset Management LLC grew its holdings in Pfizer by 4.4% in the second quarter. Fisher Asset Management LLC now owns 39,445,117 shares of the biopharmaceutical company’s stock worth $1,431,069,000 after purchasing an additional 1,671,311 shares during the period. Finally, LSV Asset Management grew its holdings in Pfizer by 2.7% in the second quarter. LSV Asset Management now owns 36,774,591 shares of the biopharmaceutical company’s stock worth $1,334,182,000 after purchasing an additional 973,497 shares during the period. 69.01% of the stock is owned by institutional investors and hedge funds.
In other Pfizer news, major shareholder Pfizer Inc acquired 55,556 shares of Pfizer stock in a transaction dated Monday, October 15th. The stock was purchased at an average cost of $18.00 per share, for a total transaction of $1,000,008.00. Following the completion of the acquisition, the insider now directly owns 21,976,484 shares of the company’s stock, valued at $395,576,712. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, insider Laurie J. Olson sold 10,214 shares of the business’s stock in a transaction dated Monday, August 13th. The stock was sold at an average price of $41.00, for a total transaction of $418,774.00. Following the transaction, the insider now owns 72,672 shares in the company, valued at $2,979,552. The disclosure for this sale can be found here. 0.06% of the stock is owned by company insiders.
A number of research firms have commented on PFE. Goldman Sachs Group restated a “neutral” rating and issued a $45.00 price target on shares of Pfizer in a report on Tuesday, August 28th. Zacks Investment Research cut shares of Pfizer from a “buy” rating to a “hold” rating in a report on Tuesday, October 16th. Independent Research set a $48.00 price target on shares of Pfizer and gave the stock a “neutral” rating in a report on Thursday, October 4th. Credit Suisse Group raised their price target on shares of Pfizer from $39.00 to $40.00 and gave the stock a “neutral” rating in a report on Wednesday, August 1st. Finally, Barclays restated a “neutral” rating and issued a $40.00 price target on shares of Pfizer in a report on Wednesday, September 26th. Two equities research analysts have rated the stock with a sell rating, fifteen have given a hold rating and eight have issued a buy rating to the stock. The stock has an average rating of “Hold” and a consensus price target of $42.95.
Shares of NYSE PFE opened at $42.93 on Friday. The stock has a market cap of $255.32 billion, a PE ratio of 16.20, a price-to-earnings-growth ratio of 2.19 and a beta of 0.96. Pfizer Inc. has a 1 year low of $33.20 and a 1 year high of $45.81. The company has a quick ratio of 0.91, a current ratio of 1.16 and a debt-to-equity ratio of 0.41.
Pfizer (NYSE:PFE) last issued its quarterly earnings data on Tuesday, October 30th. The biopharmaceutical company reported $0.78 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.75 by $0.03. The firm had revenue of $13.30 billion during the quarter, compared to analysts’ expectations of $13.53 billion. Pfizer had a net margin of 44.63% and a return on equity of 25.34%. The business’s revenue was up 1.0% on a year-over-year basis. During the same period last year, the company earned $0.67 earnings per share. As a group, research analysts anticipate that Pfizer Inc. will post 3 EPS for the current fiscal year.
The firm also recently disclosed a quarterly dividend, which will be paid on Monday, December 3rd. Stockholders of record on Friday, November 9th will be issued a dividend of $0.34 per share. This represents a $1.36 dividend on an annualized basis and a dividend yield of 3.17%. The ex-dividend date is Thursday, November 8th. Pfizer’s dividend payout ratio is currently 51.32%.
Pfizer Inc discovers, develops, manufactures, and sells healthcare products worldwide. It operates in two segments, Pfizer Innovative Health (IH) and Pfizer Essential Health (EH). The IH segment focuses on the development and commercialization of medicines and vaccines, and consumer healthcare products in various therapeutic areas, including internal medicine, vaccines, oncology, inflammation and immunology, and rare diseases, as well as consumer healthcare, such as over-the-counter brands comprising dietary supplements, pain management, gastrointestinal, and respiratory and personal care.
Recommended Story: How do investors use RSI to grade stocks?
Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with MarketBeat.com's FREE daily email newsletter.